Summary of Product Characteristics Updated 26-Mar-2020 | AstraZeneca UK Limited
Excipient with known effectLactose monohydrate 891 micrograms per delivered dose. See section 4.4.For the full list of excipients, see section 6.1.
Adults aged > 18 years:Relief medication: 1 inhalation for the relief of acute broncho-obstructive symptoms.Regular dosage: 1 inhalation once or twice daily. Some patients may need 2 inhalations once or twice daily. Prevention of exercise-induced bronchoconstriction: 1 inhalation before exercise.The daily dose for regular use should not exceed 4 inhalations, however occasionally up to a maximum of 6 inhalations may be allowed within a 24-hour period. No more than 3 inhalations should be taken on any single occasion.
Children and adolescents 6 years and older:Relief medication: 1 inhalation for the relief of acute broncho-obstructive symptoms.Regular dosage: 1 inhalation once or twice daily.Prevention of exercise-induced bronchoconstriction: 1 inhalation before exercise.The regular daily dose should not exceed 2 inhalations, however, occasionally up to a maximum of 4 inhalations may be allowed within a 24-hour period. No more than 1 inhalation should be taken on any single occasion.
Adults aged > 18 years:Regular dosage: 1 inhalation once or twice daily.The daily dose for regular use should not exceed 2 inhalations.If required, additional inhalations above those prescribed for regular therapy may be used for relief of symptoms, up to a maximum total daily dose of 4 inhalations (regular plus as required). More than 2 inhalations should not be taken on any single occasion.
ElderlyThere are no special dosing requirements for elderly patients.
Patients with hepatic or renal impairment:There are no data available for use of Oxis Turbohaler in patients with hepatic or renal impairment (see also section 5.2).
Paediatric population:Oxis Turbohaler is not recommended for use in children below 6 years due to insufficient data on safety and efficacy.NB! A lower strength (6 micrograms/dose) is also available.
Method of administration
Instructions for correct use of Oxis TurbohalerOxis Turbohaler is inspiratory flow driven which means that, when the patient inhales through the mouthpiece, the substance will follow the inspired air into the airways.Note! It is important to instruct the patient to breathe in forcefully and deeply through the mouthpiece to ensure that an optimal dose is obtained.It is important to instruct the patient never to chew or bite on the mouthpiece and never to use the inhaler if it has been damaged or if the mouthpiece has become detached.The patient may not taste or feel any medication when using Oxis Turbohaler due to the small amount of drug dispensed.Detailed instructions for use are packed together with each inhaler.
GeneralOxis Turbohaler should not be used (and is not sufficient) as the first treatment for asthma.Asthmatic patients who require therapy with long acting β2-agonists, should also receive optimal maintenance anti-inflammatory therapy with corticosteroids. Patients must be advised to continue taking their anti-inflammatory therapy after the introduction of Oxis Turbohaler even when symptoms decrease. Should symptoms persist, or treatment with β2-agonists need to be increased, this indicates a worsening of the underlying condition and warrants a reassessment of the maintenance therapy. Although Oxis Turbohaler may be introduced as add-on therapy when inhaled corticosteroids do not provide adequate control of asthma symptoms, patients should not be initiated on Oxis Turbohaler during an acute severe asthma exacerbation, or if they have significantly worsening or acutely deteriorating asthma. Serious asthma-related adverse events and exacerbations may occur during treatment with Oxis Turbohaler. Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation on Oxis Turbohaler. Once asthma symptoms are controlled, consideration may be given to gradually reducing the dose of Oxis Turbohaler. Regular review of patients as treatment is stepped down is important. The lowest effective dose of Oxis Turbohaler should be used.The maximum daily dose should not be exceeded. The long-term safety of regular treatment at higher doses than 36 micrograms per day in adults with asthma, 18 micrograms per day in children with asthma and 18 micrograms per day in patients with COPD, has not been established.Frequent need of medication (i.e. prophylactic treatment e.g. corticosteroids and long-acting β2-agonists)for the prevention of exercise-induced bronchoconstriction several times every week, despite an adequate maintenance treatment, can be a sign of suboptimal asthma control, and warrants a reassessment of the asthma therapy and an evaluation of the compliance.
Cardiovascular and endocrine disordersCaution should be observed when treating patients with thyrotoxicosis, phaeochromocytoma, hypertrophic obstructive cardiomyopathy, idiopathic subvalvular aortic stenosis, severe hypertension, aneurysm or other severe cardiovascular disorders, such as ischaemic heart disease, tachyarrhythmias or severe heart failure.
QTc prolongationFormoterol may induce prolongation of the QTc-interval. Caution should be observed when treating patients with prolongation of the QTc-interval and in patients treated with drugs affecting the QTc-interval (see section 4.5).
Diabetic patientsDue to the hyperglycaemic effects of β2-agonists, additional blood glucose monitoring is recommended initially in diabetic patients.
HypokalaemiaPotentially serious hypokalaemia may result from β2-agonist therapy. Particular caution is recommended in acute severe asthma as the associated risk may be augmented by hypoxia. The hypokalaemic effect may be potentiated by concomitant treatment with xanthine-derivatives, steroids and diuretics. The serum potassium levels should therefore be monitored.
BronchospasmAs with other inhalation therapy, the potential for paradoxical bronchospasm should be considered. If it occurs, the treatment should be discontinued immediately and alternative therapy started (see section 4.8).
Lactose intoleranceOxis Turbohaler contains lactose monohydrate 891 micrograms per delivered dose. This amount does not normally cause problems in lactose intolerant people. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Paediatric populationChildren up to the age of 6 years should not be treated with Oxis Turbohaler, as no sufficient experience is available for this group.
PregnancyThere are no adequate data from the use of formoterol in pregnant women. In animal studies formoterol has caused implantation losses as well as decreased early postnatal survival and birth weight. The effects appeared at considerably higher systemic exposures than those reached during clinical use of Oxis Turbohaler. Treatment with Oxis Turbohaler may be considered at all stages of pregnancy if needed to obtain asthma control and if the expected benefit to the mother is greater than any possible risk to the foetus. The potential risk for humans is unknown.
Breast-feedingIt is not known whether formoterol passes into human breast milk. In rats, small amounts of formoterol have been detected in maternal milk. Administration of Oxis Turbohaler to women who are breastfeeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child.
FertilityAnimal reproduction studies with formoterol have shown a somewhat reduced fertility in male rats at considerably higher systemic exposures than those reached during clinical use. Thus, these animal experimental results do not seem to be relevant in humans.
Summary of the safety profileThe most commonly reported adverse events of β2-agonist therapy, such as tremor and palpitations, tend to be mild and disappear within a few days of treatment.
Tabulated list of adverse reactionsAdverse reactions, which have been associated with formoterol are given below, listed by system organ class and frequency. Frequency are defined as: very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1 000 and <1/100), rare (≥1/10 000 and <1/1000) and very rare <1/10 000).
|System Organ Class||Frequency||Adverse Reaction|
|Uncommon||Cardiac arrhythmias, e.g. atrial fibrillation, supraventricular tachycardia, extrasystoles.|
|Very rare||Prolongation of QTc interval|
|Immune system disorders||Uncommon||Hypersensitivity reactions, e.g. bronchospasm, exanthema, urticaria, pruritus|
|Metabolic and nutrition disorders||Uncommon||Hypokalaemia|
|Musculoskeletal, connective tissue and bone disorders||Common||Muscle cramps|
|Nervous system disorders||Common||Headache*, tremor, dizziness|
|Psychiatric disorders||Uncommon||Sleep disturbances|
|Vascular disorders||Uncommon||Variations in blood pressure|
Description of selected adverse reactionsAs with all inhalation therapy, paradoxical bronchospasm may occur in very rare cases (see section 4.4).Treatment with β2-agonists may result in an increase in blood levels of insulin, free fatty acids, glycerol and ketone bodies.The excipient lactose contains small amounts of milk proteins. These may cause allergic reactions.
Reporting of suspected adverse reactionsReporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
SymptomsAn overdose would likely lead to effects that are typical of β2-agonists: tremor, headache, palpitations. Symptoms reported from isolated cases are tachycardia, hyperglycaemia, hypokalaemia, prolonged QTc-interval, arrhythmia, nausea and vomiting. Supportive and symptomatic treatment is indicated.
ManagementUse of cardioselective beta-blockers may be considered, but only subject to extreme caution since the use of β-adrenergic blocker medication may provoke bronchospasm. Serum potassium should be monitored.
Mechanism of action and pharmacodynamic effectsFormoterol is a selective β2-adrenoceptor agonist that produces relaxation of bronchial smooth muscle. Formoterol thus has a bronchodilating effect in patients with reversible airways obstruction. The bronchodilating effect sets in rapidly, within 1-3 minutes after inhalation and has a mean duration of 12 hours after a single dose.
AbsorptionInhaled formoterol is rapidly absorbed. Peak plasma concentration is reached about 10 minutes after inhalation.In a pharmacokinetic study, the mean lung deposition of formoterol after inhalation via Turbohaler was 43% of the delivered dose. The total systemic availability was around 60% of the delivered dose.
Distribution and biotransformationPlasma protein binding is approximately 50%. Formoterol is metabolised via direct glucuronidation and O-demethylation. The enzyme responsible for O-demethylation has not been identified.
EliminationThe major part of the dose of formoterol is eliminated via metabolism. Total plasma clearance and volume of distribution has not been determined. After inhalation 8-13% of the delivered dose of formoterol is excreted unmetabolised in the urine. About 20% of an intravenous dose is excreted unchanged in the urine. The terminal half-life after inhalation is estimated to be 17 hours.
Linearity/non-linearitySystemic exposure for formoterol correlates in a linear fashion to administered dose.
Special populationsThe effect of decreased liver or kidney function on the pharmacokinetics of formoterol and the pharmacokinetics in the elderly is not known. As formoterol is primarily eliminated via liver metabolism an increased exposure can be expected in patients with severe liver cirrhosis.
Horizon Place, 600 Capability Green, Luton, Bedfordshire, LU1 3LU
+44 (0)1582 838 000
+44 (0)1582 838 003
+44 (0)1582 836 000
0800 783 0033
+44 (0)1582 837 837